Acquisition Announced
Aurinia Pharmaceuticals acquisition of Kezar Life Sciences
US$51.5m equity value
Announced 30 Mar 2026 · NASDAQ: KZR · US$6.96 per share
Advisers
Kezar Life Sciences
Target
- Financial adviser
- TD Securities (as TD Cowen)
- Legal adviser
- Fairness opinion
- TD Securities (as TD Cowen)
Aurinia Pharmaceuticals
Acquirer
Not disclosed
- Target
- Kezar Life Sciences
- Acquirer
- Aurinia Pharmaceuticals
- Target based in
- United States
- Buyer based in
- Canada
- Sector
- Biotech
- Tags
- Biotech, Pharma
In the league tables
Similar deals
- TELI Pharmaceuticals and Telomir Pharmaceuticals merger US$47.1m · Biotech
- AnaptysBio outstanding common stock share buy-back Mar 2026 · US$100m · Biotech
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Amneal Pharmaceuticals acquisition of Kashiv BioSciences Apr 2026 · US$375m · Biotech
- UCB acquisition of Neurona Therapeutics Apr 2026 · US$650m · Biotech
Sources
- 30 Mar 2026 Press release (EX-99.1, exhibit), Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share sec.gov
- 30 Mar 2026 Kezar Life Sciences Acquired by Aurinia Pharmaceuticals cooley.com
- 3 Apr 2026 Press release (EX-99.1, exhibit), Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right sec.gov
- 13 Apr 2026 Tender offer statement (SC TO-T), Kezar Life Sciences, Inc. sec.gov
- 14 Apr 2026 Target response to tender offer (SC 14D9), Kezar Life Sciences, Inc. sec.gov